Welcome to the mRNA Cancer Vaccine Summit
Early 2023 saw the global partnership between Merck & Moderna highlight ground-breaking data with their personalised mRNA cancer vaccine, and shortly after, the UK government partnered with BioNTech to deliver over 10,000 mRNA personalised therapies to patients over the next 8 years - it is no secret that this innovative new cancer treatment has huge potential to improve outcomes for patients across the globe.
At this leading forum, industry experts will navigate through case-study-led presentations and interactive discussions to:
Review the Next Generation Techniques in Personalized mRNA Cancer Vaccines to Develop a More Effective Vaccine
Optimize the Antigen Selection Process to Ensure High Clinical Activity & High-Quality Immune Responses
Understand the Standards & Regulatory Requirements for mRNA Cancer Vaccines for Rapid Approvals & Commercial Readiness
As mRNA cancer vaccines appear to overcome bottlenecks with traditional cancer immunotherapy, such as instability, inefficient delivery, and weak immunogenicity, ensure you join 60+ mRNA and cancer vaccine leaders to truly remain ahead of the curve, as we revolutionize the next era of cancer immunotherapy
A snapshot of companies attending:
60+ Attendees
24+ World Class Speakers
3 Roundtable Discussions
1 Focus Day
6+ Hours of Dedicated Networking
“The relevance of neoantigens in the clinical efficacy of immunotherapy is beyond doubt. However, several fundamental and practical questions remain unanswered, and this meeting is an opportunity to discuss these issues with experts of the field.”
Ludwig Institute for Cancer Research